Asset Details
Do you wish to reserve the book?
Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study
Do you wish to request the book?
Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study
2017
Overview
Background
Moringa oleifera
Lam., an herb commonly consumed by HIV-infected people on antiretroviral therapy, inhibits cytochrome P450 3A4, 1A2 and 2D6 activity in vitro; and may alter the pharmacokinetics (PK) of antiretroviral drugs metabolized via the same pathways. However, in vitro drug interaction activity may not translate to a clinically significant effect. Therefore, the effect of moringa leaf powder on the PK of nevirapine in HIV-infected people was investigated.
Methods
Adult patients at steady-state dosing with nevirapine were admitted for 12-h intensive PK sampling following a 21-day herbal medicine washout. Blood sampling was repeated after 14 days of nevirapine and moringa (1.85 g leaf powder/day) co-administration. Nevirapine plasma concentrations were determined by liquid chromatography-tandem mass spectrometry. To assess the effect of moringa on nevirapine PK, the change in nevirapine area under the plasma concentration–time curve (AUC) was determined. The mean difference in pre- and post-moringa nevirapine, maximum concentration (C
max
) and concentration at 12 h (C
12h
) were also calculated. The PK parameters were compared by assessing the post/pre geometric mean ratios (GMRs) and associated 90% confidence intervals (CIs).
Results
Pharmacokinetics analyses were performed on the results from 11 participants for whom complete data were obtained. The post/pre GMRs and associated 90% CIs for nevirapine were 1.07 (1.00–1.14) for the AUC; 1.06 (0.98–1.16) for C
max
and 1.03 (0.92–1.16) for C
12h
.
Conclusion
Co-administration of
Moringa oleifera
Lam. leaf powder at the traditional dose did not significantly alter the steady-state PK of nevirapine.
Trial registration number
NCT01410058 (ClinicalTrials.gov)
Publisher
BioMed Central,Springer Nature B.V
Subject
Acquired immune deficiency syndrome
/ Adult
/ Aged
/ AIDS
/ Anti-HIV Agents - administration & dosage
/ Anti-HIV Agents - pharmacokinetics
/ Female
/ HIV
/ HIV Infections - drug therapy
/ Human immunodeficiency virus
/ Humans
/ LDCs
/ Leaves
/ Male
/ Medicine
/ Moringa oleifera - chemistry
/ Nevirapine - administration & dosage
/ Nevirapine - pharmacokinetics
/ Plasma
/ Powders - administration & dosage
/ Powders - isolation & purification
/ Sampling
/ Studies
/ Urine
/ Virology
